- Zacks Small Cap Research•6 days agoSNGX: Orphan Drug Designation Granted for Dusquetide for Treatment of Macrophage Activation Syndrome
On Aug. 18, 2016, Soligenix (SNGX) announced that the FDA has granted orphan drug designation to dusquetide for treatment of macrophage activation syndrome (MAS). Dusquetide has previously received orphan drug designation for the treatment of acute radiation syndrome (ARS). In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a New Drug Application, and certain tax credits.
- PR Newswire•6 days agoFDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
PRINCETON, N.J., Aug. 18, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat ...
- Capital Cube•8 days ago
Categories: Yahoo Finance Get free summary analysis Soligenix, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of Soligenix, Inc. – Emergent BioSolutions Inc., Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Limited Sponsored ADR and Athersys, Inc. (EBS-US, JNJ-US, PFE-US, TEVA-US and ATHX-US) that have also ... Read more (Read more...)
Soligenix, Inc. (SNGX)
OTC BB - OTC BB Delayed Price. Currency in USD
|Day's Range||0.58 - 0.59|
|52wk Range||0.44 - 1.49|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-9.48|
|Avg Vol (3m)||95,029|
|Dividend & Yield||N/A (N/A)|